MerckMRK
MetabolicOncology80 cited findings · profile updated 2026-08-24
152.78 USDnot live — refreshed daily
About Merck
Merck (MRK) is active in oncology research, with a focus on treatments for various cancers. The company's oncology portfolio includes pembrolizumab, which has been evaluated across multiple clinical trials for its efficacy and safety profile. Key safety findings for pembrolizumab include Grade 3 to 5 adverse events and immune-mediated adverse events.
Beyond oncology, Merck also has a therapeutic focus in metabolic disorders. This includes drugs like ertugliflozin, which has been studied for its effects on conditions such as heart failure with preserved ejection fraction and nephrocalcinosis. The company's research in this area also covers the impact of treatments on A1C levels and blood pressure.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Grade 3 to 5 AEs | 25% | MERCK SHARP DOHME — Keytruda FDA Summary Review (NDA/BLA 125514, 2020), p.10 |
| HHF HR for all ertugliflozin vs placebo | 0.70 | Merck & Co., Inc. — Segluromet EMA EPAR variation assessment report (E, p.42 |
| Proportion of participants with 1-grade change in nephrocalcinosis (combined ertugliflozin group) | 18.9% | Merck & Co., Inc. — Steglatro EMA EPAR variation assessment report (EM, p.47 |
| Grade 3 to 5 AEs in PBMCL (KN013 - C4A) | 55% | MERCK SHARP DOHME — Keytruda FDA Summary Review (NDA/BLA 125514, 2020), p.14 |
| Grade 3 to 5 AEs in rrCHD (KN087) | 33% | MERCK SHARP DOHME — Keytruda FDA Summary Review (NDA/BLA 125514, 2020), p.13 |
| IMaRs / IRRs G3 to 5 in Reference Safety Database | 6% | MERCK SHARP DOHME — Keytruda FDA Summary Review (NDA/BLA 125514, 2020), p.13 |
Key projects
- pembrolizumab (various oncology indications) — US
Grade 3 to 5 AEs for pembrolizumab 400 mg Q6W were 25% in KN555.
- pembrolizumab (rrCHD) — US
IMaRs / IRRs G3 to 5 for pembrolizumab 200 mg Q3W were 4% in KN087.
- pembrolizumab (PBMCL) — US
Grade 3 to 5 AEs for pembrolizumab 200 mg Q3W were 55% in KN013 - C4A.
- ertugliflozin (HF with preserved EF >45%) — EU
HHF HR for all ertugliflozin vs placebo was 0.70.
- ertugliflozin (nephrocalcinosis) — EU
Proportion of participants with 1-grade change in nephrocalcinosis was 18.9% in the combined ertugliflozin group.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →